Kalaris Therapeutics Inc
KLRS
NASDAQ
Biotechnology
$4.08
USD
+0.20 (+5.15%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $84.74M
Volume 28.1K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-44.26M
TTM
— YoY
Operating Cash Flow
$-41.02M
TTM
— YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 3.8 | 3.6 | 3.6 | 4.3 | 3.4 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 12.3 | 12.7 | 10.8 | 11.8 | 12.4 |
Operating Income | -12.3 | -12.7 | -10.8 | -11.8 | -12.4 |
EBITDA | -12.3 | -12.7 | -10.8 | -11.8 | -12.4 |
Other Income / Expense | 0.9 | 0.8 | 0.8 | 1.0 | 0.9 |
Total Other Income / Expense | 0.9 | 0.8 | 0.8 | 1.0 | 0.9 |
Income Before Income Taxes | -11.4 | -11.9 | -10.0 | -10.9 | -11.5 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -11.4 | -11.9 | -10.0 | -10.9 | -11.5 |
Consolidated Net Income / Loss | -11.4 | -11.9 | -10.0 | -10.9 | -11.5 |
Net Income Attributable to Common Shareholders | -11.4 | -11.9 | -10.0 | -10.9 | -11.5 |
Basic EPS | -$0.61 | -$0.64 | -$0.51 | -$0.46 | -$0.48 |
Diluted EPS | -$0.61 | -$0.64 | -$0.51 | -$0.46 | -$0.48 |
Basic Shares Outstanding | 18.7M | 18.7M | 19.6M | 23.7M | 23.8M |
Diluted Shares Outstanding | 18.7M | 18.7M | 19.6M | 23.7M | 23.8M |